Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| CTRI/2014/06/004677 | Registry Identifier | Clinical Trials Registry of India |
Not provided
Not provided
Increased mortality in the intervention arm at 50% enrolment
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study attempts to study a new ventilation mode in children with Acute respiratory distress syndrome (ARDS). Despite decades of research, no intervention has brought about a significant decrease in ARDS mortality. Moreover, most of the studies are adult-based and have been extrapolated to children. Airway pressure release ventilation (APRV) mode is hypothesized to be superior in terms of lower need for sedation, shorter duration of mechanical ventilation, etc. It is unique and the first worldwide randomized controlled trial on APRV mode in children.
We plan to recruit a minimum of 50 children aged (1 month-12 years) in each group. The study is to be conducted at the Post-Graduate Institute of Medical Education and Research (PGIMER), Chandigarh between March 2014 to March 2016. This trial would recruit children with respiratory failure and early ARDS and, randomize them to receive either conventional ventilation or the APRV mode. Rest of the supportive care has also been protocolized so that both groups receive treatment as per the existing best practices in every aspect. The primary outcome being studied is the number of ventilator-free days. The secondary outcomes include length of PICU stay, hospital stay, organ-failure free days, 28 day & 3 month survival, biomarkers of lung injury (IL-6, IL-8, Angiopoeitin-2, soluble-ICAM-1, etc), functional status, Pulmonary function tests, etc. Funding request would be sent to the Indian Council of Medical Research, New Delhi, India.
Assessing lung biomarkers like Interleukin-6 would assess the role of different modes of ventilation in acting as triggers for multi-organ dysfunction as well as for worsening lung injury. This pathbreaking research is likely to open up new avenues upon completion.
Study setting:
15-bedded pediatric intensive care unit (PICU) of a multi-specialty, tertiary referral and teaching hospital- the Advanced Pediatrics Centre (APC) in Post-Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India Study period Recruitment: January 2014 to December 2016 Data Analysis: Jan 2017 to June 2017 Study design An open-labelled, parallel-arm, efficacy/feasibility randomized controlled trial Ethics approval Ethics approval has been obtained from the Institute Ethics Committee. The study has been registered with Clinical Trials Registry - India (CTRI) (ctri.nic.in). Informed consent will be obtained from the parents/legal guardian and the conversation would be recorded using a camera (audio-visual documentation of evidence).
Sample size estimation Assuming alpha error of 5% and power of 80% with non-inferiority limit of 4 days (Standard deviation of VFDs being 8.2 days in the conventional low tidal volume ventilation group in pilot trial), sample size was calculated to be 52 per group. As this is a safety and feasibility trial, an interim analysis would be done at 50% enrolment.
Enrolment Parents or legal guardians of children who satisfy the above eligibility criteria will be invited by the investigator to participate in the study. Parents are free not to participate, or to withdraw from the study at any point of time. All children, irrespective of their enrollment in the study, will receive standard pediatric intensive care unit (PICU) care as per the unit's existing protocol. An information sheet (in Hindi/ English) furnishing details of the study will be provided to the parents. Given the fact that all these children are sedated and on mechanical ventilation, obtaining assent would not be feasible in this study.
Randomization Sequence generation A computer-generated, unstratified, block randomization with variable block sizes will be performed to determine group allocation. A person not involved in the study will perform the random number allocation and prepare opaque, sealed envelopes containing the allocation.
Concealment allocation Each pre-sealed opaque envelope would be opened only after obtaining a written consent and audio-visual record of the same. As the randomization is done using a variable block size, and prepared by a statistician not directly involved in the study, there would be no way of predicting the random allocation, thus minimizing the risk of allocation bias.
Randomization implementation After parents provide informed consent, randomization would be done within the next one hour and child initiated on appropriate mode of ventilation. The supportive care for both the groups, would be as per the attached supplementary protocols
Intervention protocol:
The Airway pressure release ventilation (APRV) intervention protocol has been designed based on the available APRV literature as of Dec 2013.
Start the child on APRV mode of ventilation with the following settings:
P HIGH would determine the degree of baseline lung inflation. A rough estimate can be obtained based on the plateau pressure requirements on the conventional mode of ventilation. Perform an inspiratory hold to ascertain the plateau pressures:
Alternatively, if P plateau cannot be measured, P HIGH can be set according to the following guide:
PaO2/ FiO2 ratio P High < 250 15-20 < 200 20-25 < 150 25-28
After initiating a particular P HIGH, a clinical assessment of lung volume needs to be followed with a chest radiograph to determine the degree of lung inflation (similar to setting of Mean airway pressure in High frequency oscillatory mode of ventilation). The child's P HIGH is adjusted to maintain optimal lung volume, without clinical or radiological evidence of hyperinflation: no signs of decreased cardiac output/ hypotension and/or the level of the diaphragm visible greater than the ninth rib.
Weaning from APRV would also be carried out in a structured, protocolized manner. The following strategies would be adopted:
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Airway pressure release ventilation arm | Experimental | This group of children would be ventilated using the Airway pressure release ventilation (APRV) mode. Restrictive fluid therapy, protocolized sedo-analgesia titration, steroid therapy, protocolized supportive care, protocolized early enteral nutrition would be provided to both the groups. Biomarkers would be measured in both groups. |
|
| Low-tidal volume ventilation arm | Active Comparator | Low-tidal volume ventilation using pressure-regulated volume control mode with target tidal volume of 6 ml/kg or less and other lung-protective strategies. Restrictive fluid therapy, protocolized sedo-analgesia titration, steroid therapy, protocolized supportive care, protocolized early enteral nutrition would be provided to both the groups. Biomarkers would be measured in both groups |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Airway Pressure Release Ventilation (APRV) | Device | This is a newer mode of ventilation that has been hypothesized to be equivalent or even superior to the conventional low-tidal volume mode of ventilation |
| Measure | Description | Time Frame |
|---|---|---|
| Twenty-eight-day ventilator-free days | 28 days |
| Measure | Description | Time Frame |
|---|---|---|
| Twenty-eight-day survival | 28 days | |
| Length of PICU stay | The children would be followed up for the duration of their PICU stay | Up to 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| Recruitment rate | Number of children recruited per month on an average | 3 years |
| Rate of enrolment among eligible children | Feasibility outcome Number of children who get enrolled in the study after consent among all eligible children |
Inclusion Criteria:
Children aged 1 month- 12 years, who are intubated and mechanically ventilated with the following criteria of Acute Respiratory Distress Syndrome:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Saptharishi L G, MBBS, MD | DM (Pediatric Critical Care) Senior Resident, Division of Pediatric critical care, Dept Of Pediatrics, Advanced Pediatrics Center, PGIMER, Chandigarh, INDIA | Principal Investigator |
| Jayashree Muralidharan, MBBS, MD | Additional Professor, Division of Pediatric critical care, Dept of Pediatrics, Advanced Pediatrics Center, PGIMER, Chandigarh, India | Study Chair |
| Sunit C Singhi, MBBS, MD | Chief, Division of Pediatric Critical Care, Professor & Head, Department of Pediatrics, Advanced Pediatrics Center, PGIMER, Chandigarh, India | Study Director |
| Arun Bansal, MBBS, MD | Assistant Professor, Division of Pediatric Critical care, Dept of Pediatrics, Advanced Pediatrics Center, PGIMER, Chandigarh, India | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pediatric Intensive care unit, Division of Pediatric Critical Care, Advanced Pediatrics Center, Post-graduate Institute of Medical Education & Research | Chandigarh | 160012 | India |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 24156844 | Background | Andrews P, Habashi N. Airway pressure release ventilation. Curr Probl Surg. 2013 Oct;50(10):462-70. doi: 10.1067/j.cpsurg.2013.08.010. No abstract available. | |
| 24064877 | Background | Andrews PL, Shiber JR, Jaruga-Killeen E, Roy S, Sadowitz B, O'Toole RV, Gatto LA, Nieman GF, Scalea T, Habashi NM. Early application of airway pressure release ventilation may reduce mortality in high-risk trauma patients: a systematic review of observational trauma ARDS literature. J Trauma Acute Care Surg. 2013 Oct;75(4):635-41. doi: 10.1097/TA.0b013e31829d3504. |
Not provided
Not provided
Permission would have to be sought from institution in this regard.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Low-tidal volume ventilation | Other | This mode of ventilation is the standard of care worldwide for ventilating children with ARDS. |
|
|
| Methylprednisolone | Drug | Children with primary ARDS presenting within the first 14 days would receive IV low dose Methylprednisolone infusion. |
|
| Restrictive fluid therapy | Other | Fluid & hemodynamics would be titrated as per pre-designed decision-making protocols |
|
| sedo-analgesia titration | Drug |
|
| Protocolized early enteral nutrition | Other | Early enteral nutrition and attempt to meet calorie-protein goals |
|
| Protocolized supportive care | Other | Eye care, chlorhexidine mouth wash Q6 hourly, Strict aseptic precautions prior to any procedures, Skin care & bed sore prevention, Adequate pulmonary toileting and chest physiotherapy, frequent position changes, limb physiotherapy, family-centered care |
|
| Biomarker Assay | Other | Biomarker Assay for patients in both arms |
|
|
| Organ-failure-free-days | 28 days |
| Time-to-recovery of lung injury | Number of days for recovery of lung injury (OI<5). | Up to 28 days |
| Number of children with adverse events | Children would be observed for incidence of adverse events during the period of PICU stay/ ventilation | 3 years |
| All-cause mortality | Three months |
| Spirometry | Forced Expiratory volume during 1st second/ Forced vital capacity | 3 months |
| Pediatric Cerebral performance category | Functional outcomes | 6 Months |
| Pediatric Overall performance category | 6 months |
| Spirometry | Forced Expiratory Volume during 1st second / Forced Vital Capacity | 6 months |
| Pediatric overall performance category | Assessment of functional outcomes | 3 months |
| Pediatric cerebral performance category | Assessment of functional outcomes | 3 months |
| Interleukin-6 levels | 72 hours of enrolment |
| Arterial lactate levels | 72 hours |
| Percentage reduction in 'oxygenation Index' | Percentage improvement in oxygenation index at 6 hours of enrolment | 6 hours |
| Radiological score | 48 hours |
| Duration of inotropic requirement | Average time frame | up to 7 days |
| Vaso-active inotropic score | 72 hours |
| Cumulative dose of sedation | 7 days |
| Cumulative dose of analgesic | 7 days |
| Cumulative dose of neuromuscular blocking agent | 7 days |
| Requirement for renal replacement therapy | Need for renal replacement therapy in the first 28 days of PICu stay or discharge/ death whichever is earlier | 28 days |
| Pediatric Logistic Organ Dysfunction (PELOD) score | 7 days |
| 3 years |
| Contamination rate | Proportion of recruited children who cross-over from one arm to another | 3 years |
| Attrition rate | Proportion of children who are lost to follow-up at 3 months | 3 months |
| Protocol adherence rate | Proportion of children where all supportive care protocols are adhered to. | 3 years |
| 24026214 | Background | Emr B, Gatto LA, Roy S, Satalin J, Ghosh A, Snyder K, Andrews P, Habashi N, Marx W, Ge L, Wang G, Dean DA, Vodovotz Y, Nieman G. Airway pressure release ventilation prevents ventilator-induced lung injury in normal lungs. JAMA Surg. 2013 Nov;148(11):1005-12. doi: 10.1001/jamasurg.2013.3746. |
| 23799354 | Background | Roy SK, Emr B, Sadowitz B, Gatto LA, Ghosh A, Satalin JM, Snyder KP, Ge L, Wang G, Marx W, Dean D, Andrews P, Singh A, Scalea T, Habashi N, Nieman GF. Preemptive application of airway pressure release ventilation prevents development of acute respiratory distress syndrome in a rat traumatic hemorrhagic shock model. Shock. 2013 Sep;40(3):210-6. doi: 10.1097/SHK.0b013e31829efb06. |
| 23247119 | Background | Roy S, Habashi N, Sadowitz B, Andrews P, Ge L, Wang G, Roy P, Ghosh A, Kuhn M, Satalin J, Gatto LA, Lin X, Dean DA, Vodovotz Y, Nieman G. Early airway pressure release ventilation prevents ARDS-a novel preventive approach to lung injury. Shock. 2013 Jan;39(1):28-38. doi: 10.1097/SHK.0b013e31827b47bb. |
| 29641221 | Derived | Lalgudi Ganesan S, Jayashree M, Chandra Singhi S, Bansal A. Airway Pressure Release Ventilation in Pediatric Acute Respiratory Distress Syndrome. A Randomized Controlled Trial. Am J Respir Crit Care Med. 2018 Nov 1;198(9):1199-1207. doi: 10.1164/rccm.201705-0989OC. |
| ID | Term |
|---|---|
| D012128 | Respiratory Distress Syndrome |
| ID | Term |
|---|---|
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D012120 | Respiration Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D045422 | Continuous Positive Airway Pressure |
| D008775 | Methylprednisolone |
| D015850 | Interleukin-6 |
| D016209 | Interleukin-8 |
| ID | Term |
|---|---|
| D011175 | Positive-Pressure Respiration |
| D012121 | Respiration, Artificial |
| D058109 | Airway Management |
| D013812 | Therapeutics |
| D012138 | Respiratory Therapy |
| D011239 | Prednisolone |
| D011246 | Pregnadienetriols |
| D011245 | Pregnadienes |
| D011278 | Pregnanes |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
| D007378 | Interleukins |
| D016207 | Cytokines |
| D036341 | Intercellular Signaling Peptides and Proteins |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
| D011506 | Proteins |
| D001685 | Biological Factors |
| D019743 | Chemokines, CXC |
| D018925 | Chemokines |
| D002630 | Chemotactic Factors |
| D018836 | Inflammation Mediators |
Not provided
Not provided